OncoSignals Weekly · Issue 12
One co-mutation identified who needed more than osimertinib. PFS doubled to 34 months. Four calls this week.
| OncoSignals
The signal behind the noise
|
Issue No. 12
11 August 2026 |
|
|
Cover · Lung
|
|
One co-mutation identified who needed more than osimertinib.
|
|
|
|
Osimertinib plus chemotherapy. In treatment-naive EGFR-mutated advanced lung cancer selected for a concurrent TP53 mutation, adding pemetrexed and carboplatin to osimertinib more than doubled median progression-free survival, from 15.6 to 34.0 months, at the cost of far more grade 3 toxicity.
|
|
34.0
months median PFS, versus 15.6 on osimertinib alone
|
0.44
hazard ratio for progression or death
|
62%
grade 3+ treatment-related events, versus 14.9
|
|
|
|
|
|
This week’s calls
Four readouts · three to act on · one to watch
|
|
|
|
Also inside
|
| 01 | The verdicts in full: four readouts, three to act on, one to watch |
| 02 | Dr. Signal’s hot take: the question was never whether |
| 03 | 100 Words on the mutations we sequence and ignore |
| 04 | The recent FDA approvals and the reader poll |
|
|
|
|
|
|
The verdicts, the game, the poll, and the full read live on the web issue.
|
|
|
OncoSignals Weekly
The signal behind the noise · every Tuesday
Curated by Dr. Rishabh Jain
Educational summaries for practising oncologists. Not medical advice. Verify against primary sources before acting.
|
|
|
